Research Profile for Athanassiadou Aglaia (Emeritus Professor)

«Return to previous page
Laboratory of Gen. Biology, Molecular Genetics
Department of Medicine
Research Activity
Gene Therapy, Thalasseamia, beta-globin, episomal vectors, S/MAR, Parkinson's Disease, alpha-synuclein,
1.Development of episomal vectors for the Gene Therapy of the HaemoglobinipAthies. Episomal vectors are formulated, based mainly on S/MAR, for the gene transfer of GFP reporter gene, and the beta-globin gene in established cell lines (K562, MEL, HeLa) as well as in primary cell cultures , mainly CD43+.The fate of the foreign DNA after entering the host cell is investigated, with regard the ensuing genetic and epigenetic envents.
2.Genetics of Parkinson’s Disease (PD). After the Genetic analysis of PD patients with autosomal dominant inheritance and the determination of Genotype –phenotype correlations, we now study the differential and epigenetically controled allelic expression of the alpha-synuclein gene involved in the disease.
Research Infrastructure
Prof. A. Athanassiadou (Molecular Genetics)
Head of the Laboratory

Other faculty members of the Laboratory of Gen. Biology

Prof. Nicholas Moschonas (Medical Molecular Genetics)
Assoc. Prof. D. Spathas (Human Cytogenetics)
Assoc. Prof. J. Zarkadis (Molecular Biology)
Ass. Prof. Z. Lygerou (Molec. Cell Biology)
Ass. Prof. A. Papachatzopoulou (Human Molec Genetics)
Heavy duty equip. for Molecular Biology, as well as Real-time PCR cycler, cDNA microarrays equip., confocal and fluorescence light microscopes, mammalian cell culture facilities, mammaliam cell immortalization facility.

Molecular Genetics Unit, a part of the laboratory, specialized in DNA Diagnostics.
Research Activities
1. Development of Episomal Vectors for the Gene Therapy of the
II. Molecular Analysis of the beta-globin gene expression in beta-Thalassaemia mutations, deriving from the Diagnostic unit.
III. Molecular Genetic Analysis of Parkinson’s Disease
•Μ.Η.Polymeropoulos, et al “Mutation in the alpha synuclein gene identified in families with Parkinson’s disease”. Science, 276:2045-2047, 1997.
• Athanassiadou A., et al"The genetic analysis of Parkinson's Disease
families carrying the G209A α-synuclein mutation". Amer.J.Hum.Genetics, 65:555-558, 1999.
•Papapetropoulos S., et al “Survival duration of Parkinson's disease in patients living in Greece who carry the G209A α-synuclein mutation”. Movement Disorders, 17 (4) 847-848, 2002
•Chow C.M., et al LCR-mediated, long-term tissue-specific gene expression within replicating episomal plasmid vectors, Gene Therapy 5 :327-36, 2002.
•Eirini P. Papapetrou, et al Genetic modification of hematopoietic stem cells with non-viral systems: past progress and future prospects Gene Therapy,12 S118-S30 2005.
•Eirini P Papapetrou, et al Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying a S/MAR element.Gene Therapy 1–12, 2005.
•Ki C-S, et al”The Ala53Thr Mutation in the α-Synuclein Gene in a Korean Family with Parkinson Disease”. Clinical Genetics 71: 471–473, 2007
1.U. of London, King' College, Guy's Hospital: Dr M.Antoniou
2.U. of London,Inst. Of Child Health,Molecular Immunology Unit:Prof.AJ Thrasher
3. Skaggs Inst. for Chemical Biology, Dept of Molecular Biology, La Jolla, California USA:Dr C. Barbas III
4.U.of Kansas, Medical Center, Kansas City,USA: Prof.K Peterson
Additional Information

Gene Editor for“Human Genome Variation Society” (HGVS), α-synuclein Gene Locus (registered as SNCA) : http://www.hgvs.orgAs part of the Locus Specific Mutation Databases, ENCOURAGED BY HUGO / MDI,